Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 692 participants.
Also called NCT07263776
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 692 participants
- Sponsor
- Registry
-
NCT07263776
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07263776. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-05 (actual); primary completion 2026-09-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
- Acronym
- IRIS-2
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Tocilizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Capital Medical University
Record details
- Record id
cardio:ct-nct07263776- Content hash
137d1b48d921486403aa2587926b1f726119fa7632c0033d823814339c086406